Abemaciclib D8

Abemaciclib D8 is a deuterated form of the FDA-approved drug Abemaciclib. It is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are enzymes involved in cell cycle progression and cell division. By inhibiting CDK4/6, Abemaciclib D8 can stop the growth and proliferation of cancer cells, particularly those found in breast cancer. Abemaciclib D8 is typically administered orally in the form of tablets, and the recommended dosage depends on the patient's age, weight, and overall health status. It is usually taken twice daily, with or without food, and should be swallowed whole with a glass of water. Patients should not crush, chew, or break the tablets as doing so may affect the way the medication is absorbed by the body. In terms of chemical information, Abemaciclib D8 has a molecular formula of C27H32D8N8O2, and a molecular weight of 484.7 g/mol. It is a white to off-white powder that is slightly soluble in water and ethanol. The deuterium labeling of Abemaciclib D8 does not affect its pharmacological activity or toxicity and is instead used as a tool in pharmacokinetic studies to track the drug's distribution, metabolism, and elimination in the body. Like all medications, Abemaciclib D8 may cause side effects, such as diarrhea, nausea, fatigue, decreased appetite, and infections. Patients taking Abemaciclib D8 should also undergo regular blood tests to monitor their liver and kidney function and to check for any potential drug interactions with other medications they may be taking.